In a press release on Monday, the retailer announced that "Beginning today, Wal-Mart, Neighborhood Market and Sam's Club pharmacies will fill prescriptions for up to 350 generic medications at $10 for a 90-day supply." Wal-Mart is also adding adding $9 generic prescriptions for up to a 30-day supplies for drugs treating osteoporosis, breast cancer, menopause and hormone deficiency, in addition to a new "$4 OTC offering," consisting of more than 1,000 products available without a prescription priced at $4 or less.
According to Wal-Mart, roughly "95 percent of the prescriptions written in the majority of therapeutic categories are included in the
But wait, there's more! At 7:26 PM EDT, Target (NYSE: TGT) responded with a press release stating that "As part of its ongoing commitment to provide exceptional value to guests and consistent with prior practices, Target will reduce prices on its prescription and over-the-counter drug offerings, remaining competitively priced with Wal*Mart."
Like most price wars, this one looks to turn out well for cash-strapped consumers.
But a word to the wise: part of the reason Wal-Mart and Target are doing this is that they want you to wander around and shop while you wait for your medication. So if you use a big-box store's pharmacy, bring a book or magazine and pull up a chair -- the savings will be nullified if you walk out of there with a $4 prescription and $30 worth of crap you don't need.

I've probably been unjustly hard on Wal-Mart Stores, Inc. (NYSE:WMT) in the past. It's not that I don't like them, it's more a case of not liking some of the moves they've made as a corporation. The one thing that really set me off was when on September 14, 2006, Wal-mart announced the phasing out of their layaway program. Without knowing the true reasons why they elected to do that, I thought that made things tougher for their potential customers who have limited buying power. I still feel that way somewhat, but I admit I failed to get Wal-mart's side of the story. The reasons Wal-Mart cited were declining use and increasing expense. They did state that they were examining other financing options for their customer's large ticket purchases. It seems like sound logic to me. Perhaps I overreacted.







